參考文獻 |
1. Andreassen, B., B. Aagnes, R. Gislefoss, M. Andreassen, and R. Wahlqvist, Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014. BMC cancer, 2016. 16(1): p. 799.
2. Society, A.C., Cancer Facts & Figures 2017. 2017, American Cancer Society Atlanta, GA.
3. Chiang, C.-J., W.-C. Lo, Y.-W. Yang, S.-L. You, C.-J. Chen, and M.-S. Lai, Incidence and survival of adult cancer patients in Taiwan, 2002–2012. Journal of the Formosan Medical Association, 2016. 115(12): p. 1076-1088.
4. Hung, C.-F., C.-K. Yang, and Y.-C. Ou, Urologic cancer in Taiwan. Japanese journal of clinical oncology, 2016. 46(7): p. 605-609.
5. Sherif, A., M.N. Jonsson, and N.P. Wiklund, Treatment of muscle-invasive bladder cancer. Expert review of anticancer therapy, 2007. 7(9): p. 1279-1283.
6. Heney, N., Natural history of superficial bladder cancer. Prognostic features and long-term disease course. The Urologic clinics of North America, 1992. 19(3): p. 429-433.
7. Nirmal, J., Y.-C. Chuang, P. Tyagi, and M.B. Chancellor, Intravesical therapy for lower urinary tract symptoms. Urological Science, 2012. 23(3): p. 70-77.
8. Rajaganapathy, B.R., M.B. Chancellor, J. Nirmal, L. Dang, and P. Tyagi, Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PloS one, 2015. 10(3): p. e0122766.
9. Ndagi, U., N. Mhlongo, and M.E. Soliman, Metal complexes in cancer therapy–an update from drug design perspective. Drug design, development and therapy, 2017. 11: p. 599.
10. Bastian, A., J.E. Thorpe, B.C. Disch, L.C. Bailey-Downs, A. Gangjee, R.K. Devambatla, J. Henthorn, K.M. Humphries, S.S. Vadvalkar, and M.A. Ihnat, A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. Journal of Pharmacology and Experimental Therapeutics, 2015. 353(2): p. 392-404.
11. Tsai, J.-R., P.-L. Liu, Y.-H. Chen, S.-H. Chou, Y.-J. Cheng, J.-J. Hwang, and I.-W. Chong, Curcumin inhibits non-small cell lung cancer cells metastasis through the Adiponectin/NF-κb/MMPs signaling pathway. PloS one, 2015. 10(12): p. e0144462.
12. Shen, C.H., J.J. Shee, J.Y. Wu, Y.W. Lin, J.D. Wu, and Y.W. Liu, Combretastatin A‐4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. British journal of pharmacology, 2010. 160(8): p. 2008-2027.
13. Mei, L., Y. Liu, H. Zhang, Z. Zhang, H. Gao, and Q. He, Antitumor and antimetastasis activities of heparin-based micelle served as both carrier and drug. ACS applied materials & interfaces, 2016. 8(15): p. 9577-9589.
14. von der Maase, H., S. Hansen, J. Roberts, L. Dogliotti, T. Oliver, M. Moore, I. Bodrogi, P. Albers, A. Knuth, and C. Lippert, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of clinical oncology, 2000. 18(17): p. 3068-3077.
15. Zhang, X.-A., S. Zhang, Q. Yin, and J. Zhang, Quercetin induces human colon cancer cells apoptosis by inhibiting the nuclear factor-kappa B Pathway. Pharmacognosy magazine, 2015. 11(42): p. 404.
16. Luo, C.-l., Y.-q. Liu, P. Wang, C.-h. Song, K.-j. Wang, L.-p. Dai, J.-y. Zhang, and H. Ye, The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomedicine & Pharmacotherapy, 2016. 82: p. 595-605.
17. Gao, X., B. Wang, X. Wei, K. Men, F. Zheng, Y. Zhou, Y. Zheng, M. Gou, M. Huang, and G. Guo, Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale, 2012. 4(22): p. 7021-7030.
18. Durgo, K., I. Halec, I. Šola, and J. Franekić, Cytotoxic and genotoxic effects of the quercetin/lanthanum complex on human cervical carcinoma cells in vitro. Archives of Industrial Hygiene and Toxicology, 2011. 62(3): p. 221-227.
19. Dolatabadi, J.E.N., A. Mokhtarzadeh, S.M. Ghareghoran, and G. Dehghan, Synthesis, characterization and antioxidant property of quercetin-Tb (III) complex. Advanced pharmaceutical bulletin, 2014. 4(2): p. 101.
20. Bravo, A. and J.R. Anacona, Metal complexes of the flavonoid quercetin: antibacterial properties. Transition Metal Chemistry, 2001. 26(1): p. 20-23.
21. Cornard, J. and J. Merlin, Spectroscopic and structural study of complexes of quercetin with Al (III). Journal of Inorganic Biochemistry, 2002. 92(1): p. 19-27.
22. Yamashita, N., H. Tanemura, and S. Kawanishi, Mechanism of oxidative DNA damage induced by quercetin in the presence of Cu (II). Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 1999. 425(1): p. 107-115.
23. Li, Y., J. Yao, C. Han, J. Yang, M.T. Chaudhry, S. Wang, H. Liu, and Y. Yin, Quercetin, inflammation and immunity. Nutrients, 2016. 8(3): p. 167.
24. Lee, S.R., S.J. Noh, J.R. Pronto, Y.J. Jeong, H.K. Kim, I.S. Song, Z. Xu, H.Y. Kwon, S.C. Kang, and E.-H. Sohn, The critical roles of zinc: beyond impact on myocardial signaling. The Korean Journal of Physiology & Pharmacology, 2015. 19(5): p. 389-399.
25. Tan, J., B. Wang, and L. Zhu, DNA binding, cytotoxicity, apoptotic inducing activity, and molecular modeling study of quercetin zinc (II) complex. Bioorganic & medicinal chemistry, 2009. 17(2): p. 614-620.
26. Knowles, M.A. and C.D. Hurst, Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature Reviews Cancer, 2015. 15(1): p. 25-41.
27. Cheung, G., A. Sahai, M. Billia, P. Dasgupta, and M.S. Khan, Recent advances in the diagnosis and treatment of bladder cancer. BMC medicine, 2013. 11(1): p. 13.
28. Babjuk, M., W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou-Redorta, and M. Rouprêt, EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder, the 2011 update. European urology, 2011. 59(6): p. 997-1008.
29. Ghervan, L., A. Zaharie, B. Ene, and F.I. Elec, Small-cell carcinoma of the urinary bladder: where do we stand? Clujul Medical, 2017. 90(1): p. 13.
30. Kim, S.-A., S.-M. Kwon, J.-A. Kim, K.W. Kang, J.-H. Yoon, and S.-G. Ahn, 5′-Nitro-indirubinoxime, an indirubin derivative, suppresses metastatic ability of human head and neck cancer cells through the inhibition of Integrin β1/FAK/Akt signaling. Cancer letters, 2011. 306(2): p. 197-204.
31. Sagiv, S., Great inventions that trick nature, new delivery system optimises bladder cancer treatment by increasing dwell time. ON drug Delivery, 2013.
32. Lu, Z., T.-K. Yeh, J. Wang, L. Chen, G. Lyness, Y. Xin, M.G. Wientjes, V. Bergdall, G. Couto, and F. Alvarez-Berger, Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. The Journal of urology, 2011. 185(4): p. 1478-1483.
33. Bochner, B.H., D.D. Sjoberg, and V.P. Laudone, A randomized trial of robot-assisted laparoscopic radical cystectomy. New England Journal of Medicine, 2014. 371(4): p. 389-390.
34. Wan, L., K. Pantel, and Y. Kang, Tumor metastasis: moving new biological insights into the clinic. Nature medicine, 2013. 19(11): p. 1450-1464.
35. Jungwirth, U., C.R. Kowol, B.K. Keppler, C.G. Hartinger, W. Berger, and P. Heffeter, Anticancer activity of metal complexes: involvement of redox processes. Antioxidants & redox signaling, 2011. 15(4): p. 1085-1127.
36. Kasprzak, M.M., A. Erxleben, and J. Ochocki, Properties and applications of flavonoid metal complexes. RSC Advances, 2015. 5(57): p. 45853-45877.
37. Mueller, J., A. Schrader, M. Schrader, T. Schnoeller, and F. Jentzmik, Management of muscle-invasive bladder cancer. Minerva urologica e nefrologica= The Italian journal of urology and nephrology, 2013. 65(4): p. 235-248.
38. Primikyri, A., G. Mazzone, C. Lekka, A.G. Tzakos, N. Russo, and I.P. Gerothanassis, Understanding zinc (II) chelation with quercetin and luteolin: a combined NMR and theoretical study. The Journal of Physical Chemistry B, 2014. 119(1): p. 83-95.
39. Williams, R.J., J.P. Spencer, and C. Rice-Evans, Flavonoids: antioxidants or signalling molecules? Free radical biology and medicine, 2004. 36(7): p. 838-849.
40. Galati, G. and P.J. O′brien, Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radical Biology and Medicine, 2004. 37(3): p. 287-303.
41. López-Lázaro, M., Distribution and biological activities of the flavonoid luteolin. Mini reviews in medicinal chemistry, 2009. 9(1): p. 31-59.
42. Afanas′ ev, I.B., A.I. Dcrozhko, A.V. Brodskii, V.A. Kostyuk, and A.I. Potapovitch, Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochemical pharmacology, 1989. 38(11): p. 1763-1769.
43. Liu, Y., K. Deng, J. Li, S. Liu, and S. Yao, Investigation of double stranded DNA damage induced by quercetin–copper (II) using piezoelectric quartz crystal impedance technique and potentiometric stripping analysis. Biophysical chemistry, 2004. 112(1): p. 69-76.
44. Hegde, A.H., S. Prashanth, and J. Seetharamappa, Interaction of antioxidant flavonoids with calf thymus DNA analyzed by spectroscopic and electrochemical methods. Journal of pharmaceutical and biomedical analysis, 2012. 63: p. 40-46.
45. Materska, M. and I. Perucka, Antioxidant activity of the main phenolic compounds isolated from hot pepper fruit (Capsicum annuum L.). Journal of Agricultural and Food Chemistry, 2005. 53(5): p. 1750-1756.
46. Vogiatzoglou, A., A.A. Mulligan, M.A. Lentjes, R.N. Luben, J.P. Spencer, H. Schroeter, K.-T. Khaw, and G.G. Kuhnle, Flavonoid intake in European adults (18 to 64 years). PloS one, 2015. 10(5): p. e0128132.
47. Nishimuro, H., H. Ohnishi, M. Sato, M. Ohnishi-Kameyama, I. Matsunaga, S. Naito, K. Ippoushi, H. Oike, T. Nagata, and H. Akasaka, Estimated daily intake and seasonal food sources of quercetin in Japan. Nutrients, 2015. 7(4): p. 2345-2358.
48. Jeong, J.H., J.Y. An, Y.T. Kwon, J.G. Rhee, and Y.J. Lee, Effects of low dose quercetin: Cancer cell‐specific inhibition of cell cycle progression. Journal of cellular biochemistry, 2009. 106(1): p. 73-82.
49. Yang, J.-H., T.-C. Hsia, H.-M. Kuo, P.-D.L. Chao, C.-C. Chou, Y.-H. Wei, and J.-G. Chung, Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metabolism and Disposition, 2006. 34(2): p. 296-304.
50. Choi, J.-A., J.-Y. Kim, J.-Y. Lee, C.-M. Kang, H.-J. Kwon, Y.-D. Yoo, T.-W. Kim, Y.-S. Lee, and S.-J. Lee, Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. International journal of oncology, 2001. 19(4): p. 837-844.
51. Yoshizumi, M., K. Tsuchiya, K. Kirima, M. Kyaw, Y. Suzaki, and T. Tamaki, Quercetin inhibits Shc-and phosphatidylinositol 3-kinase-mediated c-Jun N-terminal kinase activation by angiotensin II in cultured rat aortic smooth muscle cells. Molecular Pharmacology, 2001. 60(4): p. 656-665.
52. Bors, W., C. Michel, and M. Saran, [41] Flavonoid antioxidants: Rate constants for reactions with oxygen radicals. Methods in enzymology, 1994. 234: p. 420-429.
53. da Silva, E.L., M.K. Piskula, N. Yamamoto, J.-H. Moon, and J. Terao, Quercetin metabolites inhibit copper ion‐induced lipid peroxidation in rat plasma. FEBS letters, 1998. 430(3): p. 405-408.
54. Song, Y., S.W. Leonard, M.G. Traber, and E. Ho, Zinc deficiency affects DNA damage, oxidative stress, antioxidant defenses, and DNA repair in rats. The Journal of nutrition, 2009. 139(9): p. 1626-1631.
55. Murakami, M. and T. Hirano, Intracellular zinc homeostasis and zinc signaling. Cancer science, 2008. 99(8): p. 1515-1522.
56. Soldatović, T., E. Selimović, and B. Ličina, Antibacterial activity of zinc (II) and copper (II) terpyridine complexes.
57. Sakurai, H., A. Katoh, T. Kiss, T. Jakusch, and M. Hattori, Metallo–allixinate complexes with anti-diabetic and anti-metabolic syndrome activities. Metallomics, 2010. 2(10): p. 670-682.
58. Milosavljevic, V., Y. Haddad, M.A.M. Rodrigo, A. Moulick, H. Polanska, D. Hynek, Z. Heger, P. Kopel, and V. Adam, The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy. PloS one, 2016. 11(10): p. e0163983.
59. Zishen, W., G. Ziqi, and Y. Zhenhuan, Synthesis, characterization and anticancer activity of L-alanine Schiff base complexes of copper (II), zinc (II), nickel (II) and cobalt (II). Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry, 1990. 20(3): p. 335-344.
60. Mahmud, T., R. Rehman, A. Gulzar, A. Khalid, J. Anwar, U. Shafique, and M. Salman, Synthesis, characterization and study of antibacterial activity of enaminone complexes of zinc and iron. Arabian Journal of Chemistry, 2010. 3(4): p. 219-224.
61. Kowol, C.R., R. Trondl, V.B. Arion, M.A. Jakupec, I. Lichtscheidl, and B.K. Keppler, Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc (II) complex. Dalton Transactions, 2010. 39(3): p. 704-706.
62. Qiao, M., J.D. Iglehart, and A.B. Pardee, Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer research, 2007. 67(11): p. 5293-5299.
63. Franke, T.F., S.-I. Yang, T.O. Chan, K. Datta, A. Kazlauskas, D.K. Morrison, D.R. Kaplan, and P.N. Tsichlis, The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 1995. 81(5): p. 727-736.
64. Calvo, E., V. Bolós, and E. Grande, Multiple roles and therapeutic implications of Akt signaling in cancer. OncoTargets and therapy, 2009. 2: p. 135.
65. Yoeli-Lerner, M. and A. Toker, Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell cycle, 2006. 5(6): p. 603-605.
66. Qiao, M., S. Sheng, and A.B. Pardee, Metastasis and AKT activation. Cell cycle, 2008. 7(19): p. 2991-2996.
67. Poincloux, R., F. Lizárraga, and P. Chavrier, Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci, 2009. 122(17): p. 3015-3024.
68. Gingras, D. and R. Béliveau, Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2010. 1803(1): p. 142-150.
69. Egeblad, M. and Z. Werb, New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2002. 2(3): p. 161-174.
70. Mazzone, M., M. Baldassarre, G. Beznoussenko, G. Giacchetti, J. Cao, S. Zucker, A. Luini, and R. Buccione, Intracellular processing and activation of membrane type 1 matrix metalloprotease depends on its partitioning into lipid domains. Journal of cell science, 2004. 117(26): p. 6275-6287.
71. Itoh, Y., A. Takamura, N. Ito, Y. Maru, H. Sato, N. Suenaga, T. Aoki, and M. Seiki, Homophilic complex formation of MT1‐MMP facilitates proMMP‐2 activation on the cell surface and promotes tumor cell invasion. The EMBO journal, 2001. 20(17): p. 4782-4793.
72. Morley, M., K. Riches, C. Peers, and K. Porter, Hypoxic inhibition of human cardiac fibroblast invasion and MMP-2 activation may impair adaptive myocardial remodelling. 2007, Portland Press Limited.
73. Overall, C.M. and R.A. Dean, Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer and Metastasis Reviews, 2006. 25(1): p. 69-75.
74. Deryugina, E.I. and J.P. Quigley, Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews, 2006. 25(1): p. 9-34.
75. Hotary, K.B., E.D. Allen, P.C. Brooks, N.S. Datta, M.W. Long, and S.J. Weiss, Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell, 2003. 114(1): p. 33-45.
76. Hofmann, U.B., A.A. Eggert, K. Blass, E.-B. Bröcker, and J.C. Becker, Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer research, 2003. 63(23): p. 8221-8225.
77. Bowden, E.T., M. Barth, D. Thomas, R.I. Glazer, and S.C. Mueller, An invasion-related complex of cortactin, paxillin and PKCμ associates with invadopodia at sites of extracellular matrix degradation. Oncogene, 1999. 18(31).
78. Buccione, R., J.D. Orth, and M.A. McNiven, Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nature reviews Molecular cell biology, 2004. 5(8): p. 647-658.
79. Kalinowska, M., G. Świderski, M. Matejczyk, and W. Lewandowski, Spectroscopic, thermogravimetric and biological studies of Na (I), Ni (II) and Zn (II) complexes of quercetin. Journal of Thermal Analysis and Calorimetry, 2016. 126(1): p. 141-148.
80. Azeez, L., A.O. Oyedeji, S.O. Adewuyi, and K.O. Tijani, Syntheses, characterizations and antioxidant activities of copper complexes of quercetin as influenced by redox states. International Journal of Biological and Chemical Sciences, 2015. 9(5): p. 2712-2718.
81. Zhai, G., W. Zhu, Y. Duan, W. Qu, and Z. Yan, Synthesis, characterization and antitumor activity of the germanium-quercetin complex. 2012.
82. Raza, A., X. Xu, L. Xia, C. Xia, J. Tang, and Z. Ouyang, Quercetin-iron complex: synthesis, characterization, antioxidant, DNA binding, DNA cleavage, and antibacterial activity studies. Journal of fluorescence, 2016. 26(6): p. 2023-2031.
83. Yang, S., B. Yin, L. Xu, B. Gao, H. Sun, L. Du, Y. Tang, W. Jiang, and F. Cao, A natural quercetin-based fluorescent sensor for highly sensitive and selective detection of copper ions. Analytical Methods, 2015. 7(11): p. 4546-4551.
84. De Souza, R.F. and W.F. De Giovani, Antioxidant properties of complexes of flavonoids with metal ions. Redox Report, 2004. 9(2): p. 97-104.
85. Tu, L.-Y., J. Pi, H. Jin, J.-Y. Cai, and S.-P. Deng, Synthesis, characterization and anticancer activity of kaempferol-zinc (II) complex. Bioorganic & medicinal chemistry letters, 2016. 26(11): p. 2730-2734.
86. Dehghan, G., J.E.N. Dolatabadi, A. Jouyban, K.A. Zeynali, S.M. Ahmadi, and S. Kashanian, Spectroscopic studies on the interaction of quercetin–terbium (III) complex with calf thymus DNA. DNA and cell biology, 2011. 30(3): p. 195-201.
87. Kontogianni, V.G., P. Charisiadis, A. Primikyri, C.G. Pappas, V. Exarchou, A.G. Tzakos, and I.P. Gerothanassis, Hydrogen bonding probes of phenol–OH groups. Organic & biomolecular chemistry, 2013. 11(6): p. 1013-1025.
88. Reedijk, J., New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proceedings of the National Academy of Sciences, 2003. 100(7): p. 3611-3616.
89. Sathiyaraj, S., R.J. Butcher, and C. Jayabalakrishnan, Synthesis, characterization, DNA interaction and in vitro cytotoxicity activities of ruthenium (II) Schiff base complexes. Journal of Molecular Structure, 2012. 1030: p. 95-103.
90. Musumeci, D., L. Rozza, A. Merlino, L. Paduano, T. Marzo, L. Massai, L. Messori, and D. Montesarchio, Interaction of anticancer Ru (III) complexes with single stranded and duplex DNA model systems. Dalton Transactions, 2015. 44(31): p. 13914-13925.
91. Hecht, S.M., Bleomycin: new perspectives on the mechanism of action 1. Journal of natural products, 2000. 63(1): p. 158-168.
92. Metcalfe, C. and J.A. Thomas, Kinetically inert transition metal complexes that reversibly bind to DNA. Chemical Society Reviews, 2003. 32(4): p. 215-224.
93. Gurova, K., New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future oncology, 2009. 5(10): p. 1685-1704.
94. Costello, L., P. Feng, B. Milon, M. Tan, and R. Franklin, Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate cancer and prostatic diseases, 2004. 7(2): p. 111-117.
95. Hong, S.-H., Y.S. Choi, H.J. Cho, J.Y. Lee, T.-K. Hwang, and S.W. Kim, Induction of apoptosis of bladder cancer cells by zinc-citrate compound. Korean journal of urology, 2012. 53(11): p. 800-806.
96. Tanagornmeatar, K., C. Chaotham, B. Sritularak, K. Likhitwitayawuid, and P. Chanvorachote, Cytotoxic and anti-metastatic activities of phenolic compounds from Dendrobium ellipsophyllum. Anticancer research, 2014. 34(11): p. 6573-6579.
97. Weng, C.-J. and G.-C. Yen, Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer and Metastasis Reviews, 2012. 31(1-2): p. 323-351.
98. Sounni, N.E., L. Devy, A. Hajitou, F. Frankenne, C. Munaut, C. Gilles, C. Deroanne, E.W. Thompson, J.-M. Foidart, and A. Noël, MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. The FASEB Journal, 2002. 16(6): p. 555-564.
99. Chun, T.-H., F. Sabeh, I. Ota, H. Murphy, K.T. McDonagh, K. Holmbeck, H. Birkedal-Hansen, E.D. Allen, and S.J. Weiss, MT1-MMP–dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol, 2004. 167(4): p. 757-767.
100. Knäuper, V., H. Will, C. López-Otin, B. Smith, S.J. Atkinson, H. Stanton, R.M. Hembry, and G. Murphy, Cellular mechanisms for human procollagenase-3 (MMP-13) activation Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. Journal of Biological Chemistry, 1996. 271(29): p. 17124-17131.
101. Will, H., S.J. Atkinson, G.S. Butler, B. Smith, and G. Murphy, The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation Regulation by TIMP-2 and TIMP-3. Journal of Biological Chemistry, 1996. 271(29): p. 17119-17123.
102. Holopainen, J.M., J.A. Moilanen, T. Sorsa, M. Kivelä-Rajamäki, T. Tervahartiala, M.H. Vesaluoma, and T.M. Tervo, Activation of matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. Investigative ophthalmology & visual science, 2003. 44(6): p. 2550-2556.
103. Gkouveris, I., Matrix metalloproteinases in head and neck cancer: current perspectives. 2017.
104. Selvaraj, S., S. Krishnaswamy, V. Devashya, S. Sethuraman, and U.M. Krishnan, Flavonoid–metal ion complexes: a novel class of therapeutic agents. Medicinal research reviews, 2014. 34(4): p. 677-702.
105. Cao, W., W. Zheng, and T. Chen, Ruthenium polypyridyl complex inhibits growth and metastasis of breast cancer cells by suppressing FAK signaling with enhancement of TRAIL-induced apoptosis. Scientific reports, 2015. 5: p. srep09157.
106. Lin, J.-J., J.-H. Su, C.-C. Tsai, Y.-J. Chen, M.-H. Liao, and Y.-J. Wu, 11-epi-Sinulariolide acetate reduces cell migration and invasion of human hepatocellular carcinoma by reducing the activation of ERK1/2, p38MAPK and FAK/PI3K/AKT/mTOR signaling pathways. Marine drugs, 2014. 12(9): p. 4783-4798.
107. Zhou, R., L. Xu, M. Ye, M. Liao, H. Du, and H. Chen, Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Hormone and metabolic research, 2014. 46(11): p. 753-760.
108. Ko, H.S., H.-J. Lee, S.-H. Kim, and E.-O. Lee, Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-κB pathways. Journal of agricultural and food chemistry, 2012. 60(16): p. 4083-4089.
109. LU, C.-C., J.-S. Yang, J.-H. Chiang, M.-J. Hour, S. Amagaya, K.-W. Lu, J.-P. Lin, N.-Y. Tang, T.-H. Lee, and J.-G. Chung, Inhibition of invasion and migration by newly synthesized quinazolinone MJ-29 in human oral cancer CAL 27 cells through suppression of MMP-2/9 expression and combined down-regulation of MAPK and AKT signaling. Anticancer research, 2012. 32(7): p. 2895-2903.
110. Oudart, J.-B., M. Doué, A. Vautrin, B. Brassart, C. Sellier, A. Dupont-Deshorgue, J.-C. Monboisse, F.-X. Maquart, S. Brassart-Pasco, and L. Ramont, The anti-tumor NC1 domain of collagen XIX inhibits the FAK/PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction. Oncotarget, 2016. 7(2): p. 1516.
111. Sun, X., X. Wang, T. Chen, T. Li, K. Cao, A. Lu, Y. Chen, D. Sun, J. Luo, and J. Fan, Myelin activates FAK/Akt/NF-κB pathways and provokes CR3-dependent inflammatory response in murine system. PLoS One, 2010. 5(2): p. e9380.
112. Furuya, F., J.A. Hanover, and S.-y. Cheng, Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor. Proceedings of the National Academy of Sciences of the United States of America, 2006. 103(6): p. 1780-1785.
113. Zhou, H.Y. and A.S. Wong, Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology, 2006. 147(5): p. 2557-2566.
114. Lee, E.J., D.I. Kim, W.J. Kim, and S.K. Moon, Naringin inhibits matrix metalloproteinase‐9 expression and AKT phosphorylation in tumor necrosis factor‐α‐induced vascular smooth muscle cells. Molecular nutrition & food research, 2009. 53(12): p. 1582-1591.
115. Gong, Y., U.D. Chippada-Venkata, and W.K. Oh, Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers, 2014. 6(3): p. 1298-1327.
116. Su, Q., M. Peng, Y. Zhang, W. Xu, K.O. Darko, T. Tao, Y. Huang, X. Tao, and X. Yang, Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. American journal of cancer research, 2016. 6(2): p. 498
|